Teva Pharmaceutical Industries Limited
TEVJF
$18.50
-$1.51-7.55%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.32% | -7.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.32% | -7.99% | |||
| Cost of Revenue | 2.98% | -4.50% | |||
| Gross Profit | 11.99% | -11.46% | |||
| SG&A Expenses | 4.35% | -3.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 150.00% | -92.86% | |||
| Total Operating Expenses | 3.14% | -4.62% | |||
| Operating Income | 26.09% | -20.60% | |||
| Income Before Tax | -30.61% | 219.03% | |||
| Income Tax Expenses | -205.41% | 164.29% | |||
| Earnings from Continuing Operations | 28.18% | 180.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -110.34% | |||
| Net Income | 31.78% | 198.62% | |||
| EBIT | 26.09% | -20.60% | |||
| EBITDA | 20.15% | -17.99% | |||
| EPS Basic | 30.80% | 198.17% | |||
| Normalized Basic EPS | 35.08% | -38.75% | |||
| EPS Diluted | 33.33% | 193.99% | |||
| Normalized Diluted EPS | 35.89% | -39.86% | |||
| Average Basic Shares Outstanding | 0.79% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.17% | 2.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||